75 Word Paragraph:
ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. Its investigational mTOR inhibitor, ridaforolimus, is being developed by Merck in oncology indications and has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia.
Cancer Types Hematologic Cancers Sarcoma/Bone and Soft Tissue Cancers Categories: Biotechnology
Copyright 2013-14 © a2z, Inc. All rights reserved.